Dr Reddy's Launches USFDA-Approved Wearable ‘Nerivio’ for Migraine Management in India

Patients can use the device within 60 minutes of the onset of a headache for acute migraine treatment or every alternate day for migraine prevention.

Dr Reddy's Laboratories Ltd has launched Nerivio, an advanced USFDA approved, wearable therapy device designed for drug-free migraine management in India.

Nerivio, a prescription-based non-invasive device, is intended for both acute and prophylactic (preventive) treatment of migraines, with or without aura, for adults and adolescents aged 12 years and above. The device is worn on the upper arm and comes equipped with 18 sessions of 45 minutes each.

Utilising the Remote Electrical Neuromodulation (REN) mechanism, Nerivio specifically activates conditioned pain modulation by stimulating nerve endings. This initiates a natural pain-relieving process in the brainstem, resulting in a global effect of pain inhibition that impacts the original source of migraine pain in the head.

Patients can use the device within 60 minutes of the onset of a headache for acute migraine treatment or every alternate day for migraine prevention.

The Nerivio app, available for download on the Google Play Store and the Apple App Store, accompanies the device. The app enables users to control the intensity levels of the device and includes an interactive migraine diary for symptom logging, response tracking, and insightful analytics.

Additionally, the app features a Guided Imagery, Education, and Relaxation (GIER) protocol that, when used with Nerivio, significantly increases response rates.

MV Ramana, chief executive officer of branded markets (India and Emerging Markets) at Dr Reddy's, said, "The roll-out of Nerivio marks our entry into digital therapeutics (DTx). It is an area that is seeing increasing adoption by physicians as well as patients due to its potential to reduce pill burden and decrease dependency on non-specific medication in chronic or hard-to-treat diseases."

Given the significant burden of migraine disease, its associated symptoms, lack of effective treatment, and impact on well-being, quality of life, and productivity, Dr Reddy's is pleased to introduce Nerivio in India, Ramana added. He claims that the product, being USFDA-approved, drug-free, and non-invasive, is the first-of-its-kind for migraine in India and offers a favourable safety profile.

"We believe this product meets a genuine unmet clinical need among migraine patients. We look forward to receiving patient and HCP feedback on it. While our core generics business continues to drive our current growth, Nerivio as DTx joins our e-commerce venture' Celevida Wellness' and our recent deals to bring novel molecules such as toripalimab and pyrotinib to India, as part of our innovative products initiatives in India aimed at improving patient well-being and outcomes," added Ramana.

Founded in 1984, Dr Reddy's is a global pharmaceutical company that offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter (OTC) products.

Earlier in July this year, Dr Reddy's Laboratories Limited made a strategic decision to choose Amazon Web Services (AWS) as its cloud provider. In a collaborative effort, Dr Reddy's migrated its entire SAP platform to AWS, aiming to accelerate the development of healthcare applications and enable better patient progress tracking for healthcare providers.